Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.
Roberta RamondaMariagrazia LorenzinMaria Sole ChimentiSalvatore D'AngeloAntonio MarchesoniCarlo SalvaraniEnnio LubranoLuisa CostaYlenia Dal BoscoElena FracassiAugusta OrtolanMario FerraioliAntonio CarrieroElisa VisalliRiccardo BixioFrancesca DesiatiAlberto BergaminiElisa PedrolloAndrea DoriaRosario FotiAntonio CarlettoPublished in: Therapeutic advances in musculoskeletal disease (2022)
In a real-life clinical setting, SEC proved to be safe and effective in axSpA, mainly in naïve-patients, with a notable drug retention rate. No differences were observed between r-axSpA and nr-axSpA.